Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. For more information about this message, please visit this page: About CDC.gov.

Table 1

Clinical features of patients with adamantane-resistant or -susceptible influenza A, 2004–05 season

Clinical feature

Adamantane-resistant influenza, n = 72

Adamantane-susceptible influenza, n = 80

p value*

Median duration of illness†

12 days

13 days

0.96

No. (%) hospitalized

7 (10)

9 (12)

0.74

No. (%) fully recovered at time of follow-up interview

63 (88)

65 (81)

0.29

Median no. symptoms‡

9

8

0.59

No. (%) receiving antiviral treatment§

15 (21)

31 (39)

0.02

Median time from symptom onset to healthcare encounter

3 days

2 days

0.34

Single symptom, no. (%)‡

Fever

34 (69)

52 (74)

0.56

Cough

48 (98)

68 (97)

0.78

Headache

41 (84)

53 (76)

0.29

Muscle pain

37 (76)

45 (64)

0.57

Nasal congestion

40 (82)

54 (77)

0.55

Hoarseness

35 (71)

55 (79)

0.37

Fatigue

45 (92)

66 (94)

0.72

Ear pain

16 (33)

24 (34)

0.85

Sore throat

29 (59)

40 (57)

0.82

Difficulty breathing

28 (57)

35 (50)

0.44

Wheezing

25 (51)

42 (60)

0.33

Nausea

16 (33)

27 (39)

0.51

Vomiting

10 (20)

9 (13)

0.27

Diarrhea

12 (24)

15 (21)

0.70

Rash

2 (4)

2 (3)

1.00

Combined symptoms, no. (%)‡

Fever and cough

33 (67)

52 (74)

0.41

Fever and headache

31 (63)

43 (61)

0.84

Fever, cough, and headache

30 (61)

43 (61)

0.98

Fever and muscle pain

29 (59)

39 (56)

0.71

Fever, headache, and muscle pain

27 (55)

35 (50)

0.58

Fever, headache, muscle pain, and cough

26 (53)

35 (50)

0.74

*χ2, Fisher exact, or Wilcoxon rank sum tests performed as appropriate.†Based on 128 influenza A patients who had recovered fully at the time of follow-up interview.‡Children 6 to 23 months of age were excluded from the numerator and denominator for symptoms.§One patient had received antiviral treatment prior to influenza culture.

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.